Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Human OATP1B1 (SLCO1B1) transports sulfated bile acids and bile salts with particular efficiency.

Tóth B, Jani M, Beéry E, Heslop T, Bayliss M, Kitteringham NR, Park BK, Weaver RJ, Krajcsi P.

Toxicol In Vitro. 2018 Jun 19;52:189-194. doi: 10.1016/j.tiv.2018.06.018. [Epub ahead of print]

PMID:
29933103
2.

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Vicky FL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR.

Oncotarget. 2018 Jun 5;9(43):27104-27116. doi: 10.18632/oncotarget.25497. eCollection 2018 Jun 5.

3.

Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response.

Bowden DL, Sutton PA, Wall MA, Jithesh PV, Jenkins RE, Palmer DH, Goldring CE, Parsons JL, Park BK, Kitteringham NR, Vimalachandran D.

J Proteomics. 2018 May 15;179:53-60. doi: 10.1016/j.jprot.2018.02.030. Epub 2018 Mar 6.

PMID:
29518574
4.

Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management.

Sutton PA, Jithesh PV, Jones RP, Evans JP, Vimalachandran D, Malik HZ, Park BK, Goldring CE, Palmer DH, Kitteringham NR.

Eur J Surg Oncol. 2018 Jan;44(1):115-121. doi: 10.1016/j.ejso.2017.10.211. Epub 2017 Nov 13.

PMID:
29174709
5.

Dynamic and accurate assessment of acetaminophen-induced hepatotoxicity by integrated photoacoustic imaging and mechanistic biomarkers in vivo.

Brillant N, Elmasry M, Burton NC, Rodriguez JM, Sharkey JW, Fenwick S, Poptani H, Kitteringham NR, Goldring CE, Kipar A, Park BK, Antoine DJ.

Toxicol Appl Pharmacol. 2017 Oct 1;332:64-74. doi: 10.1016/j.taap.2017.07.019. Epub 2017 Jul 26.

PMID:
28755860
6.

Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.

Heslop JA, Kia R, Pridgeon CS, Sison-Young RL, Liloglou T, Elmasry M, Fenwick SW, Mills JS, Kitteringham NR, Goldring CE, Park BK.

Stem Cells Transl Med. 2017 Aug;6(8):1751. doi: 10.1002/sctm.12187. Epub 2017 Jun 15. No abstract available.

7.

Donor-Dependent and Other Nondefined Factors Have Greater Influence on the Hepatic Phenotype Than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.

Heslop JA, Kia R, Pridgeon CS, Sison-Young RL, Liloglou T, Elmasry M, Fenwick SW, Mills JS, Kitteringham NR, Goldring CE, Park BK.

Stem Cells Transl Med. 2017 May;6(5):1321-1331. doi: 10.1002/sctm.16-0029. Erratum in: Stem Cells Transl Med. 2017 Aug;6(8):1751.

8.

Effect of Repeated Daily Dosing with 2,4-Dinitrochlorobenzene on Glutathione Biosynthesis and Nrf2 Activation in Reconstructed Human Epidermis.

Spriggs S, Sheffield D, Olayanju A, Kitteringham NR, Naisbitt DJ, Aleksic M.

Toxicol Sci. 2016 Nov;154(1):5-15. Epub 2016 Aug 4.

PMID:
27492222
9.

A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity.

Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Antherieu S, Aerts H, Gerets HHJ, Labbe G, Hoët D, Dorau M, Schofield CA, Lovatt CA, Holder JC, Stahl SH, Richert L, Kitteringham NR, Jones RP, Elmasry M, Weaver RJ, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Park BK.

Arch Toxicol. 2017 Mar;91(3):1385-1400. doi: 10.1007/s00204-016-1745-4. Epub 2016 Jun 25.

10.

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.

Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Fredriksson Puigvert L, Dankers AC, Jacobs F, Snoeys J, Sison-Young RL, Jenkins RE, Nordling Å, Mkrtchian S, Park BK, Kitteringham NR, Goldring CE, Lauschke VM, Ingelman-Sundberg M.

Sci Rep. 2016 May 4;6:25187. doi: 10.1038/srep25187.

11.

Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile.

Heslop JA, Rowe C, Walsh J, Sison-Young R, Jenkins R, Kamalian L, Kia R, Hay D, Jones RP, Malik HZ, Fenwick S, Chadwick AE, Mills J, Kitteringham NR, Goldring CE, Kevin Park B.

Arch Toxicol. 2017 Jan;91(1):439-452. doi: 10.1007/s00204-016-1694-y. Epub 2016 Apr 2.

12.

Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.

Wong MH, Bryan HK, Copple IM, Jenkins RE, Chiu PH, Bibby J, Berry NG, Kitteringham NR, Goldring CE, O'Neill PM, Park BK.

J Med Chem. 2016 Mar 24;59(6):2396-409. doi: 10.1021/acs.jmedchem.5b01292. Epub 2016 Mar 8.

PMID:
26908173
13.

Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome.

Eakins R, Walsh J, Randle L, Jenkins RE, Schuppe-Koistinen I, Rowe C, Starkey Lewis P, Vasieva O, Prats N, Brillant N, Auli M, Bayliss M, Webb S, Rees JA, Kitteringham NR, Goldring CE, Park BK.

Sci Rep. 2015 Nov 26;5:16423. doi: 10.1038/srep16423.

14.

From mice to men: Murine models of colorectal cancer for use in translational research.

Evans JP, Sutton PA, Winiarski BK, Fenwick SW, Malik HZ, Vimalachandran D, Tweedle EM, Costello E, Palmer DH, Park BK, Kitteringham NR.

Crit Rev Oncol Hematol. 2016 Feb;98:94-105. doi: 10.1016/j.critrevonc.2015.10.009. Epub 2015 Nov 1. Review.

PMID:
26558688
15.

Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.

Shelton LM, Lister A, Walsh J, Jenkins RE, Wong MH, Rowe C, Ricci E, Ressel L, Fang Y, Demougin P, Vukojevic V, O'Neill PM, Goldring CE, Kitteringham NR, Park BK, Odermatt A, Copple IM.

Kidney Int. 2015 Dec;88(6):1261-1273. doi: 10.1038/ki.2015.286. Epub 2015 Sep 30.

16.

Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication.

Sison-Young RL, Mitsa D, Jenkins RE, Mottram D, Alexandre E, Richert L, Aerts H, Weaver RJ, Jones RP, Johann E, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Kitteringham NR, Park BK.

Toxicol Sci. 2015 Oct;147(2):412-24. doi: 10.1093/toxsci/kfv136. Epub 2015 Jul 8.

17.

Glutathione metabolism in the HaCaT cell line as a model for the detoxification of the model sensitisers 2,4-dinitrohalobenzenes in human skin.

Jacquoilleot S, Sheffield D, Olayanju A, Sison-Young R, Kitteringham NR, Naisbitt DJ, Aleksic M.

Toxicol Lett. 2015 Aug 19;237(1):11-20. doi: 10.1016/j.toxlet.2015.05.016. Epub 2015 May 26.

PMID:
26022718
18.

Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.

Heslop JA, Hammond TG, Santeramo I, Tort Piella A, Hopp I, Zhou J, Baty R, Graziano EI, Proto Marco B, Caron A, Sköld P, Andrews PW, Baxter MA, Hay DC, Hamdam J, Sharpe ME, Patel S, Jones DR, Reinhardt J, Danen EH, Ben-David U, Stacey G, Björquist P, Piner J, Mills J, Rowe C, Pellegrini G, Sethu S, Antoine DJ, Cross MJ, Murray P, Williams DP, Kitteringham NR, Goldring CE, Park BK.

Stem Cells Transl Med. 2015 Apr;4(4):389-400. doi: 10.5966/sctm.2014-0110. Epub 2015 Feb 26. Review.

19.

Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Eagle GL, Zhuang J, Jenkins RE, Till KJ, Jithesh PV, Lin K, Johnson GG, Oates M, Park K, Kitteringham NR, Pettitt AR.

Mol Cell Proteomics. 2015 Apr;14(4):933-45. doi: 10.1074/mcp.M114.044479. Epub 2015 Feb 2.

20.

Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials.

Sutton PA, Jones RP, Morrison F, Goldring CE, Park BK, Palmer DH, Malik HZ, Vimalachandran D, Kitteringham NR.

Br J Surg. 2015 Jan;102(2):e124-32. doi: 10.1002/bjs.9678.

PMID:
25627125
21.

MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.

Kia R, Kelly L, Sison-Young RL, Zhang F, Pridgeon CS, Heslop JA, Metcalfe P, Kitteringham NR, Baxter M, Harrison S, Hanley NA, Burke ZD, Storm MP, Welham MJ, Tosh D, Küppers-Munther B, Edsbagge J, Starkey Lewis PJ, Bonner F, Harpur E, Sidaway J, Bowes J, Fenwick SW, Malik H, Goldring CE, Park BK.

Toxicol Sci. 2015 Mar;144(1):173-85. doi: 10.1093/toxsci/kfu269. Epub 2014 Dec 18.

22.

Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes.

Baxter M, Withey S, Harrison S, Segeritz CP, Zhang F, Atkinson-Dell R, Rowe C, Gerrard DT, Sison-Young R, Jenkins R, Henry J, Berry AA, Mohamet L, Best M, Fenwick SW, Malik H, Kitteringham NR, Goldring CE, Piper Hanley K, Vallier L, Hanley NA.

J Hepatol. 2015 Mar;62(3):581-9. doi: 10.1016/j.jhep.2014.10.016. Epub 2014 Oct 18.

23.

Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.

Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, Alghanem AF, Cross MJ, Ellis EC, Ingelman-Sundberg M, Malik HZ, Kitteringham NR, Goldring CE, Park BK.

Free Radic Biol Med. 2015 Jan;78:202-12. doi: 10.1016/j.freeradbiomed.2014.11.003. Epub 2014 Nov 14.

24.

Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.

Walsh J, Jenkins RE, Wong M, Olayanju A, Powell H, Copple I, O'Neill PM, Goldring CE, Kitteringham NR, Park BK.

J Proteomics. 2014 Aug 28;108:171-87. doi: 10.1016/j.jprot.2014.05.007. Epub 2014 May 21.

25.

Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.

Jones RP, Sutton P, Greensmith RM, Santoyo-Castelazo A, Carr DF, Jenkins R, Rowe C, Hamlett J, Park BK, Terlizzo M, O'Grady E, Ghaneh P, Fenwick SW, Malik HZ, Poston GJ, Kitteringham NR.

Cancer Chemother Pharmacol. 2013 Aug;72(2):359-68. doi: 10.1007/s00280-013-2199-5. Epub 2013 Jun 12.

PMID:
23756919
26.

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.

Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E.

Br J Cancer. 2013 May 14;108(9):1846-53. doi: 10.1038/bjc.2013.150. Epub 2013 Apr 11.

27.

Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation.

Rowe C, Gerrard DT, Jenkins R, Berry A, Durkin K, Sundstrom L, Goldring CE, Park BK, Kitteringham NR, Hanley KP, Hanley NA.

Hepatology. 2013 Aug;58(2):799-809. doi: 10.1002/hep.26414. Epub 2013 Jul 1.

28.

The generation, detection, and effects of reactive drug metabolites.

Stachulski AV, Baillie TA, Park BK, Obach RS, Dalvie DK, Williams DP, Srivastava A, Regan SL, Antoine DJ, Goldring CE, Chia AJ, Kitteringham NR, Randle LE, Callan H, Castrejon JL, Farrell J, Naisbitt DJ, Lennard MS.

Med Res Rev. 2013 Sep;33(5):985-1080. doi: 10.1002/med.21273. Epub 2012 Oct 22. Review.

PMID:
23090860
29.

Analysis of the role of Nrf2 in the expression of liver proteins in mice using two-dimensional gel-based proteomics.

Abdullah A, Kitteringham NR, Jenkins RE, Goldring C, Higgins L, Yamamoto M, Hayes J, Park BK.

Pharmacol Rep. 2012;64(3):680-97.

30.

Human pluripotent stem cells for modeling toxicity.

Sison-Young RL, Kia R, Heslop J, Kelly L, Rowe C, Cross MJ, Kitteringham NR, Hanley N, Park BK, Goldring CE.

Adv Pharmacol. 2012;63:207-56. doi: 10.1016/B978-0-12-398339-8.00006-9. Review.

PMID:
22776643
31.

Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?

Kia R, Sison RL, Heslop J, Kitteringham NR, Hanley N, Mills JS, Park BK, Goldring CE.

Br J Clin Pharmacol. 2013 Apr;75(4):885-96. doi: 10.1111/j.1365-2125.2012.04360.x. Review.

32.

Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies.

Elliott VL, Edge GT, Phelan MM, Lian LY, Webster R, Finn RF, Park BK, Kitteringham NR.

Mol Pharm. 2012 May 7;9(5):1291-301. doi: 10.1021/mp200587m. Epub 2012 Apr 18.

PMID:
22480236
33.

Microwave ablation of ex vivo human liver and colorectal liver metastases with a novel 14.5 GHz generator.

Jones RP, Kitteringham NR, Terlizzo M, Hancock C, Dunne D, Fenwick SW, Poston GJ, Ghaneh P, Malik HZ.

Int J Hyperthermia. 2012;28(1):43-54. doi: 10.3109/02656736.2011.610428.

PMID:
22235784
34.

Assessing the safety of stem cell therapeutics.

Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, French N, Hanley NA, Kelly L, Kitteringham NR, Kurth J, Ladenheim D, Laverty H, McBlane J, Narayanan G, Patel S, Reinhardt J, Rossi A, Sharpe M, Park BK.

Cell Stem Cell. 2011 Jun 3;8(6):618-28. doi: 10.1016/j.stem.2011.05.012. Review. Erratum in: Cell Stem Cell. 2011 Aug 5;9(2):176.

35.

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.

Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP, Goldring CE, Park BK.

Mol Cancer. 2011 Apr 13;10:37. doi: 10.1186/1476-4598-10-37.

36.

Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.

Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK, Kitteringham NR, Goldring CE, Hanley NA.

Stem Cell Res. 2010 Jul;5(1):4-22. doi: 10.1016/j.scr.2010.02.002. Epub 2010 Mar 4. Review.

37.

Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF-kappaB.

Chia AJ, Goldring CE, Kitteringham NR, Wong SQ, Morgan P, Park BK.

Biochem Pharmacol. 2010 Aug 1;80(3):410-21. doi: 10.1016/j.bcp.2010.04.004. Epub 2010 Apr 21.

38.

Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver.

Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, Goldring CE, Powell H, Sanderson C, Williams S, Higgins L, Yamamoto M, Hayes J, Park BK.

J Proteomics. 2010 Jun 16;73(8):1612-31. doi: 10.1016/j.jprot.2010.03.018. Epub 2010 Apr 24.

39.

Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway.

Copple IM, Lister A, Obeng AD, Kitteringham NR, Jenkins RE, Layfield R, Foster BJ, Goldring CE, Park BK.

J Biol Chem. 2010 May 28;285(22):16782-8. doi: 10.1074/jbc.M109.096545. Epub 2010 Apr 8.

40.

Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach.

Rowe C, Goldring CE, Kitteringham NR, Jenkins RE, Lane BS, Sanderson C, Elliott V, Platt V, Metcalfe P, Park BK.

J Proteome Res. 2010 May 7;9(5):2658-68. doi: 10.1021/pr1001687. Erratum in: J Proteome Res. 2010 Aug 6;9(8):4313-4.

PMID:
20373825
41.

The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity.

Copple IM, Goldring CE, Kitteringham NR, Park BK.

Handb Exp Pharmacol. 2010;(196):233-66. doi: 10.1007/978-3-642-00663-0_9. Review.

PMID:
20020265
42.

High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo.

Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, Kitteringham NR, Park BK.

Toxicol Sci. 2009 Dec;112(2):521-31. doi: 10.1093/toxsci/kfp235. Epub 2009 Sep 25.

PMID:
19783637
43.

A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ.

Tonack S, Aspinall-O'Dea M, Jenkins RE, Elliot V, Murray S, Lane CS, Kitteringham NR, Neoptolemos JP, Costello E.

J Proteomics. 2009 Dec 1;73(2):352-6. doi: 10.1016/j.jprot.2009.07.009. Epub 2009 Aug 3.

PMID:
19651253
44.

Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo.

Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, Park BK.

Proteomics Clin Appl. 2009 Jun;3(6):720-9. doi: 10.1002/prca.200800222.

PMID:
21136982
45.

A mechanistic investigation into the irreversible protein binding and antigenicity of p-phenylenediamine.

Jenkinson C, Jenkins RE, Maggs JL, Kitteringham NR, Aleksic M, Park BK, Naisbitt DJ.

Chem Res Toxicol. 2009 Jun;22(6):1172-80. doi: 10.1021/tx900095r.

PMID:
19469519
46.

Extract of Ginkgo biloba induces glutathione-S-transferase subunit-P1 in vitro.

Liu XP, Goldring CE, Wang HY, Copple IM, Kitteringham NR, Park BK.

Phytomedicine. 2009 May;16(5):451-5. doi: 10.1016/j.phymed.2008.11.001. Epub 2009 Jan 7.

PMID:
19131229
47.

Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics.

Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1229-39. doi: 10.1016/j.jchromb.2008.11.013. Epub 2008 Nov 14. Review.

PMID:
19041286
48.

The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system.

Copple IM, Goldring CE, Jenkins RE, Chia AJ, Randle LE, Hayes JD, Kitteringham NR, Park BK.

Hepatology. 2008 Oct;48(4):1292-301. doi: 10.1002/hep.22472.

PMID:
18785192
49.

Albumin and immunoglobulin depletion of human plasma.

Jenkins RE, Kitteringham NR, Greenough C, Park BK.

Methods Mol Biol. 2008;425:15-25. doi: 10.1007/978-1-60327-210-0_2.

PMID:
18369883
50.

Glutathione-S-transferase pi as a model protein for the characterisation of chemically reactive metabolites.

Jenkins RE, Kitteringham NR, Goldring CE, Dowdall SM, Hamlett J, Lane CS, Boerma JS, Vermeulen NP, Park BK.

Proteomics. 2008 Jan;8(2):301-15. doi: 10.1002/pmic.200700843.

PMID:
18203258

Supplemental Content

Loading ...
Support Center